Clinical Study Investigating Use of the Biomarker mSEPT9 for
Post-Treatment Evaluation of CRC Patients (CRC Monitoring)
This study will evaluate whether the epigenetic biomarker mSEPT9 or a combination of mSEPT9 with the epigenetic biomarker mRASSF2A can be used for the detection of CRC recurrence after curative resection of the colorectal tumor.
A quantitative assay for detection of mSEPT9 and mRASSF2A has been developed for use in this potential CRC monitoring indication.
Study Start: | November 2010 |
Study Location: | Oncology centers and practices in Germany |
Study Scope: | approx. 200 patients |
Study Coordinator: | Prof. Hans-Joachim Schmoll, Clinic and Polyclinic for Internal Medicine IV, |
